Soligenix Inc Stock OTC Bulletin Board
Equities
US8342232084
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Apr. 25 | Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa | CI |
Apr. 15 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Financials (USD)
Sales 2024 * | 800K | Sales 2025 * | 900K | Capitalization | 5.9M |
---|---|---|---|---|---|
Net income 2024 * | -8M | Net income 2025 * | -9M | EV / Sales 2024 * | 7.37 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 6.55 x |
P/E ratio 2024 * |
-0.66
x | P/E ratio 2025 * |
-0.73
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.93% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 57 | 06-07-31 | |
Jonathan Guarino
DFI | Director of Finance/CFO | 51 | 19-09-10 |
Richard Straube
CTO | Chief Tech/Sci/R&D Officer | 72 | 14-01-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 57 | 06-07-31 | |
Gregg Lapointe
BRD | Director/Board Member | 65 | 09-02-28 |
Robert Rubin
BRD | Director/Board Member | 78 | 09-09-30 |
1st Jan change | Capi. | |
---|---|---|
-3.16% | 102B | |
+1.27% | 96.29B | |
+2.13% | 22.18B | |
-15.80% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.64% | 16.36B | |
+4.69% | 13.97B | |
+32.28% | 12.17B |